JNJ-42165279

Generic Name
JNJ-42165279
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H17ClF2N4O3
CAS Number
1346528-50-4
Unique Ingredient Identifier
AH2E5UQ11Y
Background

Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

Phase 2
Completed
Conditions
Autism Spectrum Disorder
Interventions
Drug: Placebo
Drug: JNJ-42165279
First Posted Date
2018-09-10
Last Posted Date
2024-12-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
78
Registration Number
NCT03664232
Locations
🇺🇸

BioBehavioral Research of Austin PC, Austin, Texas, United States

🇺🇸

Harmonex Neuroscience Research, Dothan, Alabama, United States

🇺🇸

Southwest Autism Research and Resource Center, Phoenix, Arizona, United States

and more 6 locations

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-42165279
Drug: Placebo
First Posted Date
2018-06-20
Last Posted Date
2018-10-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
12
Registration Number
NCT03564379
Locations
🇺🇸

WCCT Global, LLC, Cypress, California, United States

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Phase 2
Completed
Conditions
Depressive Disorder
Anxiety
Interventions
Other: Placebo
Drug: JNJ-42165279
First Posted Date
2015-07-15
Last Posted Date
2022-11-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
161
Registration Number
NCT02498392

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Phase 2
Completed
Conditions
Phobic Disorders
Interventions
Drug: Placebo
Drug: JNJ-42165279
First Posted Date
2015-05-04
Last Posted Date
2021-09-02
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
150
Registration Number
NCT02432703

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 11C-MK-3168
Drug: JNJ-42165279
First Posted Date
2014-06-23
Last Posted Date
2015-09-28
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
15
Registration Number
NCT02169973

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-42165279
Drug: Itraconazole
First Posted Date
2014-02-19
Last Posted Date
2014-04-23
Lead Sponsor
Janssen Pharmaceutica N.V., Belgium
Target Recruit Count
16
Registration Number
NCT02065739
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy